Int J Cancer by Silver, Sharon R. et al.
Cancer incidence and metolachlor use in the Agricultural Health 
Study: An update
Sharon R. Silver1, Steven J. Bertke1, Cynthia J. Hines1, Michael C.R. Alavanja2, Jane A. 
Hoppin3, Jay H. Lubin2, Jennifer A. Rusiecki4, Dale P. Sandler5, and Laura E. Beane 
Freeman2
1Division of Surveillance, Hazard Evaluations and Field Studies, National Institute for 
Occupational Safety and Health, Cincinnati, OH
2Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and 
Genetics, National Cancer Institute, Bethesda, MD
3Department of Biological Sciences, North Carolina State University, Raleigh, NC
4Department of Preventive Medicine and Biostatistics, Uniformed Services University of the 
Health Sciences, Bethesda, MD
5Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle 
Park, NC
Abstract
Metolachlor, a widely used herbicide, is classified as a Group C carcinogen by the U.S. 
Environmental Protection Agency based on increased liver neoplasms in female rats. 
Epidemiologic studies of the health effects of metolachlor have been limited. The Agricultural 
Health Study (AHS) is a prospective cohort study including licensed private and commercial 
pesticide applicators in Iowa and North Carolina enrolled 1993–1997. We evaluated cancer 
incidence through 2010/2011 (NC/IA) for 49,616 applicators, 53% of whom reported ever using 
metolachlor. We used Poisson regression to evaluate relations between two metrics of metolachlor 
use (lifetime days, intensity-weighted lifetime days) and cancer incidence. We saw no association 
between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or 
most site-specific cancers. For liver cancer, in analyses restricted to exposed workers, elevations 
observed at higher categories of use were not statistically significant. However, trends for both 
lifetime and intensity-weighted lifetime days of metolachor use were positive and statistically 
significant with an unexposed reference group. A similar pattern was observed for follicular cell 
lymphoma, but no other lymphoma subtypes. An earlier suggestion of increased lung cancer risk 
at high levels of metolachlor use in this cohort was not confirmed in this update. This suggestion 
of an association between metolachlor and liver cancer among pesticide applicators is a novel 
finding and echoes observation of increased liver neoplasms in some animal studies. However, our 
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findings for both liver cancer and follicular cell lymphoma warrant follow-up to better 
differentiate effects of metolachlor use from other factors.
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Metolachlor is a chloroacetanilide herbicide that was first registered in 1976 and is used 
primarily on corn, soybeans and sorghum. The US Environmental Protection Agency 
(USEPA) has classified metolachlor as a “possible human carcinogen” based on mixed 
results in rodent studies, with a statistically significant increase in liver neoplasms seen in 
female rats at high dose levels.1
Epidemiologic studies of the health effects of metolachlor are quite limited. An ecologic 
study in Maryland found a nonsignificantly increased risk of childhood bone cancer in areas 
with detectable levels of metolachlor in groundwater supplies2; interpretation of these results 
is limited by the presence of multiple contaminants in the groundwater.
To date, the health effects of occupational exposure to metolachlor have been studied only in 
the Agricultural Health Study (AHS), a prospective study that includes commercial and 
private pesticide applicators in Iowa and private pesticide applicators in North Carolina. 
Methodological details of this cohort study have been described elsewhere.3,4 Both a nested 
case–control study of lung cancer5 and a prospective follow-up through 2002 of applicators 
who used metolachlor6 observed increased risks for lung cancer with high lifetime days of 
use. These analyses saw weaker associations with intensity-weighted lifetime days, a metric 
that accounts for exposure-modifying factors.7 Associations between metolachlor use and 
incidence of a number of other cancers were also examined in the prospective study.6 The 
study found a decreasing risk of prostate cancer with increasing lifetime days of reported 
use. Rectal cancer was significantly elevated in the highest lifetime-days category and 
nonsignificantly elevated using intensity-weighted lifetime days. However, cases were 
sparse, and the elevations were attenuated when nonexposed applicators were used for 
comparison.6 No statistically significant associations with ever use of metolachlor were seen 
in AHS studies of multiple risk factors for specific cancers in applicators: melanoma,8 
pancreatic cancer9 and colon or rectal cancer.10
The current evaluation extended follow-up of the cohort (through 2010 in North Carolina 
and 2011 in Iowa) to further evaluate the associations between occupational use of 
metolachlor and cancer incidence. This update also incorporated new exposure information 
from a follow-up interview. While exposure–response relations for all cancers with at least 
20 cases in metolachlor users were examined, results for lung, prostate and rectal cancer 
were of particular interest in light of previous analyses, and liver cancer was of interest 
because of the animal data.
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Pesticide applicators were enrolled at pesticide licensing sessions conducted between 1993 
and 1997 in Iowa (private and commercial applicators) and North Carolina (private 
applicators only). Of the 57,310 licensed restricted-use applicators in this cohort, we 
excluded 6,259 because they did not provide sufficient information to quantify days of 
metolachlor use; 1,094 because of a cancer diagnosis other than nonmelanoma skin cancer 
before enrollment in the AHS; and 341 who had no person-time at risk. Of the 49,616 
eligible applicators, 36 were included in the lifetime-days usage analyses but excluded from 
analyses of intensity-weighted lifetime days because they lacked data for the latter metric.
We ascertained cancer incidence by linking cohort records to cancer registry files through 
2010 for North Carolina and 2011 for Iowa. In addition, to determine vital status, we linked 
cohort members to the death registries of these two states and to the National Death Index.
Exposure assessment for the AHS has been described in depth elsewhere.7,11–13 At 
enrollment, self-administered questionnaires were used to collect data on lifetime pesticide 
use and application practices, demographic and lifestyle data and personal and family 
history of cancer. Approximately 5 years later (1999–2005), applicators completed a 
telephone questionnaire about pesticide use during the most recent year of application as an 
indicator of pesticide use over the interval since enrollment.14,15 Overall, 36,342 applicators 
(63% of the full cohort) responded to this second questionnaire. We evaluated two metrics: 
lifetime days and intensity-weighted lifetime days of metolachlor use. The lifetime days 
metric was the summation of self-reported use from the enrollment and follow-up 
questionnaires.11 The weighting factors for the intensity-weighted lifetime days metric were 
designed to account for use of personal protective equipment, methods of pesticide 
application, whether the applicator repaired pesticide application equipment and whether the 
applicator mixed pesticides. These factors were modified since the previous analyses of 
metolachlor to incorporate refinements based on field measurement data for subgroups of 
the AHS population, resulting in minor changes to the intensity-weighted lifetime days.7 In 
addition, analyses included a data-driven multiple imputation for days of use for applicators 
who did not complete the 1999–2005 questionnaire.15
Statistical analysis
With the availability of 5-year follow-up (AHS phase 2) information, we computed 
metolachlor use as a time-dependent quantity. We categorized lifetime days and intensity-
weighted lifetime days of use with quartiles based on the distribution among exposed cancer 
cases (excluding nonmelanoma skin cancers). As in the original analysis,6 we observed that 
demographic characteristics for groups with higher metolachlor use were more similar to 
those using less metolachlor than to unexposed applicators, and therefore again produced 
two sets of analyses: one restricted to person-time after first metolachlor use and a second 
without this restriction.
We used Poisson regression to generate rate ratios (RRs) and 95% confidence intervals (CIs) 
for the relations among metolachlor use and all cancers combined, as well as specific cancer 
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sites, and the MIANALYZE procedure to determine variances for 95% CI calculation when 
using phase 2 imputed data. We used SAS (version 9.3; SAS Institute, Cary, NC) for all 
analyses. We accumulated person-time-at-risk for each 2-year calendar increment from the 
date of enrollment (1993–1997) through the earliest of the study end date (December 31, 
2010 in North Carolina and December 31, 2011 in Iowa), date of first cancer diagnosis 
(other than non-melanoma skin cancer), date of death or the date first moved out of state. 
We used the midpoint value of each exposure category treated as a continuous variable to 
test for linear trend. All tests were two-sided and conducted at α = 0.05. To account for 
disease latency, we selected a 5-year lag for the primary analyses, discounting the five most 
recent years of exposure, but also conducted unlagged analyses for comparison with earlier 
AHS analyses.
We adjusted all models for attained age (using restricted cubic splines), cigarette smoking 
(never/low/high, with the median value of pack-years among smokers used to demarcate low 
and high categories), alcohol use reported in the year before enrollment (never, and tertiles 
of number of drinks per month among applicators reporting drinking), family history of 
cancer at any site in first-degree relatives (yes/no), applicator type (private, commercial) and 
state of residence (Iowa/North Carolina). For oral cavity cancers, we also assessed the 
effects of adjusting for ever use of oral tobacco (snuff or chewing tobacco). We adjusted for 
sex and race (white, nonwhite) for all cancers combined and for race for cancers of the 
prostate and lung. For the other outcomes of interest, all or almost all cases occurred in 
white males, so all applicators were retained in the analyses with no adjustment for sex or 
race (with the exception of exclusions for sex-specific cancers). We identified the five most 
highly correlated pesticides by categorizing unlagged intensity-weighted lifetime days for 
each pesticide and calculating the correlation with quartiles of intensity-weighted lifetime 
days for metolachlor. To adjust for these pesticides in the analyses, we categorized exposure 
to each as never, low and high, with the median of intensity-weighted lifetime days used to 
differentiate low from high exposure. A separate category was used to indicate missing data 
for each correlated pesticide.
Results
Among the 49,616 applicators meeting inclusion criteria, 26,505 (53%) reported any 
metolachlor use (Table 1). Follow-up for all applicators averaged 14.9 years, double the 
average follow-up available for the first analysis of cancer incidence and metolachlor use. 
The applicators were almost all white (97%) and male (97%). For most demographic and 
exposure characteristics, differences between applicators who did not use metolachlor and 
those with any use were larger than differences among the groups with different levels of 
use. Applicators reporting metolachlor usage were more likely to have consumed alcohol in 
the past year and to have at least a high school education. The largest difference was state of 
residence, with >70% of applicators in each usage category residing in Iowa, compared to 
57% of those who did not use metolachlor. Alcohol consumption and smoking differed by 
state, with the former higher in Iowa and the latter higher in North Carolina.
Applicators in the highest metolachlor usage quartile differed in some respects from the 
applicators who did not use metolachlor and those who used less metolachor; in particular, 
Silver et al. Page 4













many more in the highest quartile were commercial applicators (20.6% of applicators in 
quartile 4 vs. <8% of applicators in each of the other usage groups and in nonusers of 
metolachlor). Applicators in the highest usage group were also most likely to have used one 
or more of the highly correlated pesticides: imazethapyr, alachlor, atrazine, dicamba and/or 
trifluralin.
Among applicators who ever used metolachlor, with low-exposed applicators as the referent, 
results for all cancers combined and for most specific cancer sites exhibited few trends or 
significant elevations in the top quartiles for lifetime days or intensity-weighted lifetime 
days of use with a 5-year lag (Table 2). However, several cancers did show increased (oral 
cavity, rectal and testicular cancer) or decreased (leukemia and prostate and stomach cancer) 
risk with higher levels of metolachlor use. Neither point estimates nor trends were 
statistically significant. For oral cavity malignancies, adjusting for oral tobacco (snuff or 
dip) use had little effect on the results.
Although NHL as a grouped outcome showed no evidence of a trend, RRs for the follicular 
cell lymphoma subtype16 were elevated in all categories for lifetime days and, in the third 
and fourth quartiles, for intensity-weighted lifetime days, though trends were not statistically 
significant. Liver cancer showed nonstatistically significant increased risks in the third and 
fourth quartiles for both exposure metrics; the tests for trend were not significant (p = 0.10). 
Because liver cancer was the only outcome with fewer than five cases in the lowest 
metolachlor use category with cutpoints based on all cancers combined, we also performed 
alternate analyses using categories based on the equal distribution of exposed liver cancer 
cases. The results were similar (data not shown) to those presented above, although risk 
estimates increased and the trend approached statistical significance (p = 0.07) for intensity-
weighted lifetime days.
Analyses with the unexposed as the referent did not change the conclusions for most 
outcomes (Table 3). Point estimates for lung and pancreatic cancers were lower, with all 
exposed categories in deficit in these analyses, but neither the category estimates nor trends 
attained statistical significance. For leukemia, the small suggestion of a negative trend 
disappeared, and for rectal cancer, point estimates in the top three quartiles decreased. For 
all outcomes, findings were similar when unlagged data were used (results not shown). 
Results were also similar for sensitivity analyses excluding applicators who did not respond 
to the second questionnaire and analyses removing applicator type from the models.
The most notable results of the analyses with the unexposed referent were for follicular cell 
lymphoma and liver cancer, both of which had statistically significant positive trends. 
Follicular cell lymphoma showed elevations in all but the first quartile, with the highest 
lifetime-days quartile attaining statistical significance; trends for both metolachlor use 
metrics were statistically significant. A test for homogeneity did not show statistically 
significant differences between NHL subtypes, but cases were sparse for some subtypes, 
including follicular cell. For liver cancer, we observed statistically significant increases in 
the third and fourth quartiles and statistically significant trends for both lifetime days and 
intensity-weighted lifetime days.
Silver et al. Page 5














This updated examination of metolachlor use and cancer in the AHS cohort found 
suggestions of positive associations between metolachlor use and incidence of both liver 
cancer and follicular cell lymphoma, though there were few exposed cases for either 
outcome (n = 25 and 32, respectively). To our knowledge, this is the first occupational 
epidemiology study to report positive associations between metolachlor exposure and these 
two outcomes. The findings for liver cancer are of particular interest, given observations of 
increased liver neoplasms in some animals exposed to metolachlor.
Studies underlying the USEPA classification of metolachor as a “possible human 
carcinogen” found mixed results in rodents, with female rats showing the most strongly 
positive results for hepatic neoplasms.17 No increased tumor incidence was observed in 
Charles River DC-1 mice.18 Other hepatic effects in rats included induction of liver 
enzymes,19,20 a dose-related increase in hepatocellular hypertrophy (male rats)17 and cystic 
cholangioma at high doses (female rats).17 A study comparing the effects on cells of 
metolachlor and alachlor, a structural analog, found metolachlor to be less cytotoxic than 
alachlor to human hepatoma (HepG2) cells.21 Another study found metolachlor to be less 
cytotoxic than alachlor and acetochlor to rat hepatocytes but of equivalent potency in human 
hepatocytes. In addition to the hepatic effects,22 increased incidence of nasal cavity tumors 
was reported in male rats in a high dose group.23 In our study, there were too few female 
applicators to evaluate sex differences for specific cancer sites.
The potential mechanism of metolachlor hepatic carcinogenicity is unknown, and results 
appear to differ for rat and human cells and subcellular components. Metolachlor has been 
shown to induce hepatic CYP2B1/2 activity in male rats.19 Researchers have suggested an 
activation pathway leading to a DNA-reactive dialykylbenzoquinone imine, but a study 
found that while rat liver microsomes exposed to metolachlor produced one important 
intermediate [2-chloro-N-(2-methyl-6-ethylphenyl)acetamide], human liver microsomes did 
not.18 However, other investigators have shown greater potential for cytotoxicity in human 
than in rat hepatocytes.22 Clarification of the reasons for these differences would facilitate 
evaluation of the potential for carcinogenicity in humans.
We also observed statistically significant positive trends for follicular lymphoma for both 
lifetime and intensity-weighted lifetime days. While a previous AHS analysis of metolachlor 
did not find associations between metolachlor use and either NHL or lymphohematopoietic 
cancers in general,6 an AHS examination of cancer incidence related to alachlor use reported 
a positive, statistically significant trend for lymphohematopoietic cancers.24 In human 
lymphocytes, metolachlor has not been found to induce sister chromatid exchanges.25 
Whether metolachlor produces a clastogenic response in human lymphocytes is unclear, 
with both positive20 and negative26 reports.
The findings from this update of the cohort are similar to those in the earlier report on cancer 
incidence and metolachlor use6 for rectal cancer, with nonsignificant elevations in all 
categories above the referent but no significant trend. Prostate cancer continues to have 
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decreasing risks with increasing lifetime days of exposure, although the results in the update 
are not statistically significant.
The excess lung cancer at higher lifetime days of metolachlor exposure previously seen in 
the cohort5,6 is absent in this update, with no observed exposure response and no notable or 
statistically significant increase in any exposure quartile. When we replicated the original 
analysis using the original exposure information collected at enrollment, but incorporating 
the 6 years of additional follow-up, the relations with both lifetime days and intensity-
weighted lifetime days were less strong than in the previous analysis.6 Quite a number of 
lung cancer cases have accrued in the interim; while the original analysis had 46 
metolachlor-using cases with no lag imposed, the current analysis has almost 200 such cases 
with a 5-year lag. When we then added the exposure information from the follow-up 
questionnaire, the exposure response was dampened further, although this effect of the 
additional exposure data was more modest than the effect of extending follow-up. 
Sensitivity analyses, which (i) removed the imputed values and (ii) limited analysis to 
participants who completed the follow-up questionnaire, did not produce large changes in 
the results. Pesticides most correlated with metolachlor use differed in the two studies, but 
an additional sensitivity analysis using the original pesticide confounders also failed to 
explain the difference between the two analyses. Collectively, these results suggest that the 
addition of person-time and new cases with different metolachlor use patterns account for 
the majority of the attenuation of the previously observed relation between metolachlor and 
lung cancer. In the update, only 15% of applicators reported using metolachlor in the most 
recent farming year, in contrast with 48% reporting ever-use of metolachlor on the 
enrollment questionnaire; 20% of the cohort were no longer farming as of phase 2 follow-
up. In addition, the volume of metolachlor used in the United States has declined since the 
mid-1990s,27,28 and increased use of personal protective equipment, other changes in 
application methods and changes in metolachlor formulation during the follow-up period 
may have decreased exposures. The apparent attenuation of lung cancer risk may indicate 
that diminishing use has reduced risk, that the previous results were due to chance or that 
latency may be important. In our study, with unexposed applicators in the reference group, 
the relation is in fact negative, though not statistically significant.
Study strengths include the size of the cohort, which comprises 26,505 metolachlor users, as 
well as 23,111 nonusers of this herbicide. The questionnaires used were quite 
comprehensive, including information on use of other pesticides, use of personal protective 
equipment and methods of application. The imputation method used was developed based 
on applicator characteristics and, for metolachlor, data withheld from development of the 
imputation algorithm were quite consistent with results generated by the algorithm.15 Recall 
bias was minimized by initial collection of pesticide use and lifestyle information at study 
entry, and assessments of the reliability of pesticide use report data in the study have been 
positive.12,13
Our inability to distinguish between two metolachlor isomers, S-metolachlor and R-
metolachlor, is a limitation of the study. S-metolachlor is the more herbicidally active 
isomer. The original metolachlor marketed was a 50–50 mixture of the R- and S-isomers. In 
1997, the manufacturer registered a new product, S-metolachlor, which contained 88% S-
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isomer, 12% R-isomer. S-metolachlor can be applied at a lower rate than the old product 
because it has more of the active isomer. The old formulation was taken off the market in 
September 1999, but was brought back onto the market as a generic in 2003.29 Chronic 
toxicity testing on Daphnia magna found R-metolachlor to be significantly more toxic with 
respect to longevity and reproductive outcomes than S-metolachlor30; smaller amounts of 
product with higher concentrations of S-metolachlor can be applied because of its greater 
efficacy, leading to the potential for reduced applicator exposures.
Additional follow-up time would allow for sensitivity analyses using a multiplier assuming 
reduced intensity calculation for days accrued from 1999 forward. However, one study 
reported that while S-metolachlor did not increase the frequency of micronuclei, a 
commercial formulation of S-metolachlor did; the authors suggest that additional 
xenobiotics in the commercial formulation may be responsible for this effect.31 If “other or 
inert” ingredients (which may vary over time and by commercial formulation and are often 
not identified in commercial products), rather than metolachlor itself, are responsible for 
apparent associations, then accounting for the change in the relative proportions of the 
isomers may do little to improve assessment of the relations between metolachlor and these 
malignancies.
The finding of a positive exposure–response relation between liver cancer and metolachlor 
use comprises the first report suggesting that the increased liver neoplasms observed in rats 
may have a correlate in humans. The trends for liver cancer results, as well as for follicular 
cell lymphoma, were positive regardless of the reference group but attained statistical 
significance in analyses using unexposed person-time as the referent. Additional follow-up 
would facilitate assessment of whether the differences in the results reflect greater statistical 
power with a larger reference category or other exposure-related factors that we were unable 
to control for in our analyses. Further follow-up would also permit better assessment of the 
role of latency in these associations, as well as evaluation of the role of metolachlor 
exposure in other health outcomes, particularly those for which cases are sparse or for which 
a longer lag period may be more biologically plausible.
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Metolachlor, a widely used herbicide, has been classified as a possible human carcinogen 
(Group C) by the U.S. Environmental Protection Agency based on an increase in liver 
neoplasms in female rats. This update of pesticide applicators in the Agricultural Health 
Study is the first occupational epidemiology assessment to report positive associations 
between metolachlor use and liver cancer in humans. For both liver cancer and follicular 
cell lymphoma, lifetime and intensity-weighted lifetime days of metolachor use showed 
positive trends that were statistically significant when applicators with no metolachlor 
use were used as the referent group
Silver et al. Page 11
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